MUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccines

Cancer Immunology Immunotherapy

Volumn 48, Issue 10, 2000, Pages 588-594

  Acres, Bruce ^a   Apostolopoulos, Vasso ^c   Balloul, Jean Mare ^a   Wreschner, Danny ^b   Xing, Pei Xiang ^c   Ali Hadji, Dahlila ^a   Bizouarne, Nadine ^a   Kieny, Marie Paule ^a   McKenzie, Ian F C ^c  

^a TRANSGENE S A   (France)

^b TEL AVIV UNIVERSITY   (Israel)

^c AUSTIN RESEARCH INSTITUTE   (Australia)

Author keywords

Cancer; Cytotoxic T cells; Immunotherapy; MUC1; Transgenic mice

Indexed keywords

GLUTATHIONE TRANSFERASE; HYBRID PROTEIN; INTERLEUKIN 2; MANNAN; TUMOR VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; AUTOIMMUNITY; CANCER IMMUNIZATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; IMMUNOHISTOLOGY; IMMUNOREACTIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; STEM CELL; TRANSGENIC MOUSE;

EID: 0033989671     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00006677     Document Type: Article

References (41)

1. 1. Acres B, Hareuveni M, Balloul JM, Kieny MP (1993) Vaccinia virus MUC1 immunization of mice: immune response and protection against the growth of murine tumours bearing the MUC1 antigen. J Immunother 14:136
2. 2. Apostolopoulos V, Xing PX, Trapani JA, McKenzie IFC (1993) Production of anti-breast cancer monoclonal antibodies using a glutathione-S-transferase-MUC1 bacterial fusion protein. Br J Cancer 67:713
3. 3. Apostolopoulos V, Xing PX, McKenzie IFC (1994) Murine immune response to cells transfected with human MUC1: immunisation with cellular and synthetic antigens. Cancer Res 54:5186
4. 4. Apostolopoulos V, Pietersz G, Loveland B, Sandrin M, McKenzie I (1995) Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses. Proc Natl Acad Sci USA 92:10128
5. 5. Apostolopoulos V, Loveland BE, Pietersz GA, McKenzie IFC (1995) CTL in mice immunised with human mucin 1 are MHC-restricted. J Immunol 155:5089
6. 6. Apostolopoulos V, Pietersz G, McKenzie IFC (1996) Cell-mediated immune responses to MUC1 fusion protein coupled to mannan. Vaccine 14:930
7. 7. Apostolopoulos V, Karanika V, Haurum J, McKenzie IFC (1997) Induction of HLA-A2 restricted cytotoxic T lymphocytes to the MUC1 human breast cancer antigen. J Immunol 159:5211
8. 8. Balloul J, Acres R, Geist M, Dott K, Stefani L, Schmitt D, Drillien R, Spehner D, McKenzie I, Xing P, Kieny M (1994) Recombinant MUC1 vaccinia virus: a potential vector for immunotherapy of breast cancer. Cell Mol Biol 40:49
9. 9. Barnd D, Lan M, Metzger R, Finn O (1989) MHC-unrestricted recognition of tumour-associated mucins by human cytotoxic T cells. Proc Natl Acad Sci USA 86:7159
10. 10. Bizouarne N, Balloul JM, Schatz C, Acres B, Kieny MP (1996) Immunotherapy of breast cancer using a recombinant vaccinia virus expressing the human MUC1 and IL2 genes. In: Calvo F, Crépin M, Magdelenat H (eds). Breast cancer, advances in biology and therapeutic. John Libby Eurotext, Montrouge, pp 303
11. 11. Burchell J, Gendler S, Taylor-Papadimitriou J, Girling A, Lewis A, Millis R, Lamport D (1987) Development and characterization of breast reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res 47:5476
12. 12. Ding L, Lalani E, Reddish M, Koganty R, Wong T, Samuel J, Yacyshyn M, Meikle A, Fung P, Taylor-Papadimitriou J, Longenecker M (1993) Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 mucin gene: effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene. Cancer Immunol Immunother 36:9
13. 13. Fey K, Melchers I, Eichmann K (1983) Quantitative studies on T cell diversity. IV. Mathematical analysis of multiple limiting populations of effector and suppressor T cells. J Exp Med 158:40
14. 14. Fung Y, Madej M, Koganty R, Longenecker M (1990) Active specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumour-associated glycoconjugate. Cancer Res 50:4308
15. 15. Gendler S, Taylor-Papadimitriou J, Duhig T, Rothbard J, Burchell J (1988) A highly immunogenic region of human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J Biol Chem 263:12820
16. 16. Gong J, Chen D, Kashiwaba M, Li Y, Chen L, Takeuchi H, Qu H, Rowse GJ, Gendler SJ, Kufe D (1998) Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. Proc Natl Acad Sci USA 95:6279
17. 17. Goydos J, Elder E, Whiteside T, Finn O, Lotze M (1996) A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J Surg Res 63:298
18. 18. Graham RA, Burchell JM, Beverley P, Taylor-Papadimitriou J (1996) Intramuscular immunisation with MUC1 cDNA can protect C57 mice challenged with MUC1-expressing syngeneic mouse tumour cells. Int J Cancer 65:664
19. 19. Hareuveni M, Tsarfaty I, Zaretsky J, Kotke P, Horev J, Zrihan S, Weiss M, Green S, Lathe R, Keydar I, Wreschner D (1990) A transcribed gene containing a variable number of tandem repeats codes for a human epithelial tumour antigen. Eur J Biochem 189:475
20. 20. Hareuveni M, Gautier C, Kieny MP, Wreschner D, Chambon P, Lathe R (1990) Vaccination against tumour cells expressing breast cancer epithelial tumour antigen. Proc Natl Acad Sci USA 87:9498
21. 21. Ho J, Bi N, Yan P, Yuan M, Norton K, Kim Y (1991) Characterization of new pancreatic-reactive monoclonal antibodies directed against purified mucin. Cancer Res 51:372
22. 22. Hu J, Kindsvogel W, Busby S, Bailey M, Shi Y, Greenberg P (1993) An evaluation of the potential to use tumour-associated antigens as targets for antitumour T cell therapy using transgenic mice expressing a retroviral tumour antigen in normal lymphoid tissue. J Exp Med 177:1681
23. 23. Jallat S, Perraud F, Dalemans W, Bailand A, Dieterle A, Faure T, Meulien P, Pavirani A (1990) Characterization of recombinant human factor IX expressed in transgenic mice and in derived transimmortalized hepatic cell lines. EMBO J 9:3295
24. 24. Karanikas V, Hwang L, Pearson J, Ong C, Apostolopoulos V, Vaughan H, Xing P, Jamieson G, Pietersz G, Tait B, Thynne G, McKenzie IFC (1998) Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J Clin Invest 100:403
25. 25. Keiny MP, Lathe R, Drillien R, Spehner D, Skoky S, Schmitt D, Wiktor T, Koprowski H, Lecocq JP (1984) Expression of the rabies virus glycoprotein from a recombinant Vaccinia virus. Nature 312:163
26. 26. Kjeldson T, Clausen H, Hirohashi S, Ogawa T, Ijima H, Hakamori S (1988) Preparation and characterization of monoclonal antibodies directed to the tumour-associated O-linked sialosyl-2-6 N-acetyl galactosaminyl (sialosyl-Tn) epitope. Cancer Res 48:2214
27. 27. Lathe R, Vilotte J, Clark A (1987) Plasmid and bacteriophage vectors for excision of intact inserts. Gene 57:193
28. 28. Lees CJ, Apostolopoulos V, Acres BA, Ong CS, Popovski V, McKenzie IFC (1999) The effect of T1 and T2 cytokines on the cytotoxic T cell response to mannan-MUC1. Cancer Immunol (in press)
29. 29. Lefkovits I, Waldmann H (1984) Limiting dilution analysis of the cells of the immune system. I. The clonal basis of the immune response. Immunol Today 5:265
30. 30. Lofthouse SA, Apostolopoulos V, Pietersz GA, McKenzie IFC (1997) Induction of T1 (CTL) and/or T2 (antibody) response to a mucin-1 tumour antigen. Vaccine 15:1586
31. 31. Matzinger P (1994) Tolerance, danger, and the extended family. Annu Rev Immunol 12:991
32. 32. Peat N, Gendler S, Lalani E, Duhig TJ, Taylor-Papadimitriou J (1992) Tissue-specific expression of a human polymorphic epithelial mucin (MUC1) in transgenic mice. Cancer Res 52:1954
33. 33. Rowse GG, Temparo RM, VanLith ML, Hollingsworth MA, Gendler SJ (1998) Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model. Cancer Res 58:315
34. 34. Rughetti A, Turchi V, Apollini C, Ghetti G, Scambia G, Panici P, Roncucci G, Manusco S, Frati L, Nuti M (1993) Human B-cell response to polymorphic epithelial mucin. Cancer Res 53:2457
35. 35. Scholl SM, Balloul JM, Le Goc G, Bizouarne N, Schatz C, Kieny MP, Vincent-Salomon A, Deneux L, Tartour E, Fridman H, Pouillart P, Acres RB (1999) A recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in breast cancer. J Immunother (in press)
36. 36. Stauss H, Dahl M, Sadovnikova E (1997) Tumour-reactive cytotoxic lymphocytes specific for normal cellular proteins. Biochem Soc Trans 25:540
37. 37. Taswell C (1981) Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis. J Immunol 126:1614
38. 38. Von Mensdorff-Pouilly S, Gourevitch MM, Kenemans P, Verstraeten AA, Litvinov SV, Kamp GJ van, Meijer S, Vermorken J, Hilgers J (1996) Humoral immune response to polymorphic epithelial mucin (MUC-1) in patients with benign and malignant breast tumours. Eur J Cancer 8:1325
39. 39. Xing PX, Tjandra JJ, Stacker SA, Teh JG, Thompson CH, McLaughlin PJ, McKenzie IFC (1989) Monoclonal antibodies reactive with mucin expressed in breast cancer. Immunol Cell Biol 67:183.
40. 40. Xing P, Prenzoska J, Quelch K, McKenzie IFC (1992) Second generation anti-MUC1 peptide monoclonal antibodies. Cancer Res 52:2310
41. 41. Xing P, Michael M, Apostolpoulos V, Prenzoska J, Marshal C, Bishop J, McKenzie I (1995) Phase I study of synthetic MUC1 peptides in breast cancer. Int J Oncol 6:1283